相关实验视频
Updated: Jun 24, 2025

11:10
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
16.2K
使用新型糖尿病药物的胰腺炎:使用FDA营销后不良事件报告系统 (FAERS) 数据库的真实数据研究
Khalidah A Alenzi1,2, Deemah Alsuhaibani3, Bader Batarfi1
1Society of Pharmacovigilance, Jeddah, Saudi Arabia.
Frontiers in pharmacology
|June 11, 2024
概括
葡萄糖样-1受体激动剂 (GLP-1 RAs) 和二乙酶4 (DPP-4) 抑制剂与胰腺炎的更高风险有关. 利拉格卢提德是一种GLP-1RA,与胰腺炎有显著的关联.
科学领域:
- 药物监督 药物监督 药物监督
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
背景情况:
- 胰腺炎是致病的重要原因,可以是药物诱导的.
- 葡萄糖类-1受体激动剂 (GLP-1RA) 越来越多地被认为是潜在的胰腺炎风险.
- 与其他低血糖药物进行比较风险评估至关重要.
研究的目的:
- 为了比较与GLP-1RAs相关的胰腺炎风险与-葡萄糖共运输体-2 (SGLT2) 抑制剂和二乙酶4 (DPP-4) 抑制剂的风险.
- 在这些类别中识别可能带来更高风险的特定药物.
- 分析药物不良事件信号,使用已建立的药物监测方法.
主要方法:
- 使用了FDA不良事件报告系统 (FAERS) 数据库 (2019-2021年).
- 使用传统和贝叶斯统计方法,包括ROR,PRR,EBGM和IC,以检测安全信号.
- 研究的胰腺炎报告与GLP-1RA,SGLT2抑制剂和DPP-4抑制剂有关.
主要成果:
- 总共分析了2313份胰腺炎报告.
- GLP-1RA主要与胰腺炎 (70.2%) 相关,其次是DPP-4 (15%) 和SGLT2抑制剂 (14.7%).
- 对DPP-4抑制剂 (13.2) 和GLP-1RA (9.65) 观察到胰腺炎的显著报告几率 (ROR). 利拉格卢提德在GLP-1RA中显示出最高的相关性 (ROR:6.83).
结论:
- DPP-4抑制剂和GLP-1RA与胰腺炎的实质性风险有关.
- 特别是利拉格卢提德,在GLP-1RA中显示出与胰腺炎的显著关联.
- 需要进一步研究药物诱导胰腺炎的机制和临床影响.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Acute Pancreatitis II: Clinical Manifestations and Management
118
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
118
Chronic Pancreatitis I: Introduction
86
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
86

